Iambic Therapeutics files for a US initial public offering, backed by Nvidia and Qatar Investment Authority
According to CNA Business, Iambic Therapeutics filed for a US initial public offering, backed by Nvidia and Qatar Investment Authority, with J.P. Morgan, Jefferies, BofA Securities, and Citigroup as underwriters for a Nasdaq listing under the symbol IAM. The San Diego-based drug developer, founded in 2019 as Entos, is advancing IAM1363 in early-stage trials and has raised about $461.8 million since inception; AbbVie revealed a multi-year AI-driven discovery collaboration with Iambic.
Key facts
- 01Backed by Nvidia and Qatar Investment Authority.
- 02Underwriters include J.P. Morgan, Jefferies, BofA Securities and Citigroup.
- 03Plans to list on Nasdaq under the symbol IAM.
- 04Advanced candidate IAM1363 in early-stage trials.
- 05Founded in 2019 as Entos; San Diego-based.
AI-generated from the sources below. Always check the originals.
How each country tells it
So far our sources show coverage from one country. Perspectives appear once we find reports from a second country.
Sources
Summaries are AI-generated from the linked sources and may contain errors; always check the originals. We summarise and link; we never republish articles. Photos come from openly licensed libraries, official publicity material and brand logos, credited to their sources. If you own an image and want it credited differently or removed, email info@coda.news and we will act promptly.